Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|UNC1999||EZH1 inhibitor 3 EZH2 inhibitor 18||UNC1999 inhibits EZH1 and EZH2, resulting in decreased H3K27 tri-methylation, and potentially leading to decreased tumor cell proliferation (PMID: 23614352, PMID: 24183969).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ARID1A mutant||ovarian cancer||sensitive||UNC1999||Preclinical - Cell culture||Actionable||In a preclinical study, UNC1999 inhibited growth of ovarian cancer cell lines harboring ARID1A mutations in culture (PMID: 25686104).||25686104|
|ATRX fusion||neuroblastoma||predicted - sensitive||UNC1999||Preclinical - Cell line xenograft||Actionable||In a preclinical study, treatment with UNC1999 resulted in reduced proliferation and increased apoptosis of neuroblastoma cell lines harboring in-frame ATRX fusions in culture, and decreased tumor growth in a neuroblastoma cell line xenograft model harboring an ATRX fusion (PMID: 31631027).||31631027|
|EZH2 Y641N||diffuse large B-cell lymphoma||sensitive||UNC1999||Preclinical||Actionable||In a preclinical study, UNC1999 treatment reduced H3K27me3 levels, decreased proliferation, and increased cell death in diffuse large B-cell lymphoma cells harboring an EZH2 Y641N mutation in cell culture (PMID: 23614352).||23614352|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|